Androulidaki, Ariadne
Liu, Fanyu
Bebber, Christina M. https://orcid.org/0000-0002-7841-7493
Kisis, Ilmars https://orcid.org/0000-0001-6207-3991
Sakthivelu, Vignesh https://orcid.org/0009-0000-1652-0850
Hunold, Pascal https://orcid.org/0000-0002-7087-5908
Koerner, Lioba https://orcid.org/0000-0003-4364-479X
Dahlhaus, Alina https://orcid.org/0000-0001-9055-0695
Yapici, Fatma Isil https://orcid.org/0009-0004-9298-8315
Grimm, Christina https://orcid.org/0000-0002-4676-8870
Pacholewska, Alicja https://orcid.org/0000-0002-4888-4883
Tishina, Sofya https://orcid.org/0000-0002-8232-496X
Doskotz, Franka https://orcid.org/0009-0001-9353-4639
Torres Fernández, Lucia A. https://orcid.org/0000-0002-8890-6258
Stroh, Jenny
Abdallah, Ali T.
Beck, Julia
Mulalic, Lejla
Schmitt, Anna
Grüll, Holger
Persigehl, Thorsten
Quaas, Alexander
Peifer, Martin https://orcid.org/0000-0002-5243-5503
Brägelmann, Johannes https://orcid.org/0000-0002-1306-2169
Reinhardt, H. Christian https://orcid.org/0000-0001-5706-9349
Nieper, Pascal
Hänsel-Hertsch, Robert https://orcid.org/0000-0002-2835-4471
Thomas, Roman K. https://orcid.org/0000-0001-9132-4876
George, Julie https://orcid.org/0000-0002-4272-3683
Schweiger, Michal R. https://orcid.org/0000-0002-2139-3478
Pasparakis, Manolis https://orcid.org/0000-0002-9870-0966
Beleggia, Filippo https://orcid.org/0000-0003-0234-7094
von Karstedt, Silvia https://orcid.org/0000-0002-7816-5919
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ID 413326622)
Deutsche Forschungsgemeinschaft (ID 414786233)
Deutsche Forschungsgemeinschaft (ID 325931972)
Deutsche Forschungsgemeinschaft (ID 455784452)
Bundesministerium für Bildung und Forschung (01ZX2201A)
Article History
Received: 22 September 2025
Accepted: 24 November 2025
First Online: 18 December 2025
Competing interests
: H.C.R. received consulting and lecture fees from AbbVie, AstraZeneca, Roche, Janssen-Cilag, Novartis, Vertex and Merck. H.C.R. received research funding from Gilead and AstraZeneca. H.C.R. is a co-founder of CDL Therapeutics GmbH. R.K.T. was a founder and shareholder of and consultant to PearlRiver Bio (now part of Centessa), a shareholder of Centessa and founder, shareholder and CEO of DISCO Pharmaceuticals. All other authors declare that they have no competing interests.